Benefit-Risk Analysis of Upadacitinib Compared with Adalimumab in the Treatment of Patients with Moderate-to-Severe Rheumatoid Arthritis.

MLA

Conaghan, Philip, et al. “Benefit-Risk Analysis of Upadacitinib Compared with Adalimumab in the Treatment of Patients with Moderate-to-Severe Rheumatoid Arthritis.” Rheumatology and Therapy, vol. 9, no. 1, Feb. 2022, pp. 191–206. EBSCOhost, https://doi.org/10.1007/s40744-021-00399-5.

APA

Conaghan, P., Cohen, S., Burmester, G., Mysler, E., Nash, P., Tanaka, Y., Rigby, W., Patel, J., Shaw, T., Betts, K. A., Patel, P., Liu, J., Sun, R., & Fleischmann, R. (2022). Benefit-Risk Analysis of Upadacitinib Compared with Adalimumab in the Treatment of Patients with Moderate-to-Severe Rheumatoid Arthritis. Rheumatology and Therapy, 9(1), 191–206. https://doi.org/10.1007/s40744-021-00399-5

Chicago

Conaghan, Philip, Stanley Cohen, Gerd Burmester, Eduardo Mysler, Peter Nash, Yoshiya Tanaka, William Rigby, et al. 2022. “Benefit-Risk Analysis of Upadacitinib Compared with Adalimumab in the Treatment of Patients with Moderate-to-Severe Rheumatoid Arthritis.” Rheumatology and Therapy 9 (1): 191–206. doi:10.1007/s40744-021-00399-5.